These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 28013405

  • 21. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.
    Reiter Y, Brinkmann U, Kreitman RJ, Jung SH, Lee B, Pastan I.
    Biochemistry; 1994 May 10; 33(18):5451-9. PubMed ID: 7910034
    [Abstract] [Full Text] [Related]

  • 22. [Soluble expression of recombinant immunotoxin against human bladder carcinoma and its anti-tumor activity].
    Chao K, He D, Yang H, Zhang Z, Lin Q, Guo AG, Huang HL.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Sep 10; 20(5):568-71. PubMed ID: 15367349
    [Abstract] [Full Text] [Related]

  • 23. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
    Stoessel A, Groysbeck N, Guyot L, Barret L, Nominé Y, Nguekeu-Zebaze L, Bender A, Voilquin L, Lutz T, Pallaoro N, Blocat M, Deville C, Masson M, Zuber G, Chatton B, Donzeau M.
    Bioconjug Chem; 2020 Oct 21; 31(10):2421-2430. PubMed ID: 32996763
    [Abstract] [Full Text] [Related]

  • 24. Molecular construction and characterization of a novel exotoxin fusion protein that selectively blocks the B7:CD28 costimulatory signal system.
    Xi Y, Yuan Z, Zhang H, Guan H, Kong F, Liu N, Liang F, Cui J, Guo S, Sun Y, Xi C.
    J Immunother; 2006 Oct 21; 29(6):586-95. PubMed ID: 17063121
    [Abstract] [Full Text] [Related]

  • 25. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli.
    Joshi BH, Puri RK.
    Protein Expr Purif; 2005 Feb 21; 39(2):189-98. PubMed ID: 15642470
    [Abstract] [Full Text] [Related]

  • 26. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
    Della Cristina P, Castagna M, Lombardi A, Barison E, Tagliabue G, Ceriotti A, Koutris I, Di Leandro L, Giansanti F, Vago R, Ippoliti R, Flavell SU, Flavell DJ, Colombatti M, Fabbrini MS.
    Microb Cell Fact; 2015 Feb 13; 14():19. PubMed ID: 25889802
    [Abstract] [Full Text] [Related]

  • 27. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors.
    Schmidt M, Maurer-Gebhard M, Groner B, Köhler G, Brochmann-Santos G, Wels W.
    Oncogene; 1999 Mar 04; 18(9):1711-21. PubMed ID: 10208432
    [Abstract] [Full Text] [Related]

  • 28. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
    Kreitman RJ, Hansen HJ, Jones AL, FitzGerald DJ, Goldenberg DM, Pastan I.
    Cancer Res; 1993 Feb 15; 53(4):819-25. PubMed ID: 8428363
    [Abstract] [Full Text] [Related]

  • 29. Expression and purification of recombinant immunotoxin--a fusion protein stabilizes a single-chain Fv (scFv) in denaturing condition.
    Kim SH.
    Protein Expr Purif; 2003 Jan 15; 27(1):85-9. PubMed ID: 12509988
    [Abstract] [Full Text] [Related]

  • 30. B3(Fab)-PE38M: a recombinant immunotoxin in which a mutant form of Pseudomonas exotoxin is fused to the Fab fragment of monoclonal antibody B3.
    Choe M, Webber KO, Pastan I.
    Cancer Res; 1994 Jul 01; 54(13):3460-7. PubMed ID: 8012967
    [Abstract] [Full Text] [Related]

  • 31. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
    Reiter Y, Brinkmann U, Jung SH, Lee B, Kasprzyk PG, King CR, Pastan I.
    J Biol Chem; 1994 Jul 15; 269(28):18327-31. PubMed ID: 7913461
    [Abstract] [Full Text] [Related]

  • 32. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
    Tur MK, Huhn M, Thepen T, Stöcker M, Krohn R, Vogel S, Jost E, Osieka R, van de Winkel JG, Fischer R, Finnern R, Barth S.
    Cancer Res; 2003 Dec 01; 63(23):8414-9. PubMed ID: 14679004
    [Abstract] [Full Text] [Related]

  • 33. The immunotoxin activity of exotoxin A is sensitive to domain modifications.
    Amiri Tehranizadeh Z, Sankian M, Fazly Bazzaz BS, Chamani J, Mehri S, Baratian A, Saberi MR.
    Int J Biol Macromol; 2019 Aug 01; 134():1120-1131. PubMed ID: 31129209
    [Abstract] [Full Text] [Related]

  • 34. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.
    Beers R, Chowdhury P, Bigner D, Pastan I.
    Clin Cancer Res; 2000 Jul 01; 6(7):2835-43. PubMed ID: 10914732
    [Abstract] [Full Text] [Related]

  • 35. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
    Chen H, Gao J, Lu Y, Kou G, Zhang H, Fan L, Sun Z, Guo Y, Zhong Y.
    J Control Release; 2008 Jun 24; 128(3):209-16. PubMed ID: 18450313
    [Abstract] [Full Text] [Related]

  • 36. EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway.
    Yang Y, Tian Z, Ding Y, Li X, Zhang Z, Yang L, Zhao F, Ren F, Guo R.
    J Immunol Res; 2018 Jun 24; 2018():1090287. PubMed ID: 30596104
    [Abstract] [Full Text] [Related]

  • 37. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
    Bera TK, Williams-Gould J, Beers R, Chowdhury P, Pastan I.
    Mol Cancer Ther; 2001 Dec 24; 1(2):79-84. PubMed ID: 12467225
    [Abstract] [Full Text] [Related]

  • 38. GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials.
    Woo JH, Liu JS, Kang SH, Singh R, Park SK, Su Y, Ortiz J, Neville DM, Willingham MC, Frankel AE.
    Protein Expr Purif; 2008 Mar 24; 58(1):1-11. PubMed ID: 18160309
    [Abstract] [Full Text] [Related]

  • 39. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
    Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham MC, Pennell LK, Hogge DE, Kreitman RJ, Frankel AE.
    Protein Expr Purif; 2004 Jan 24; 33(1):123-33. PubMed ID: 14680969
    [Abstract] [Full Text] [Related]

  • 40. In vitro and in vivo studies of antitumor effects of the recombinant immunotoxin MSH-PE38KDEL on melanoma.
    Hui Q, Ma J, Song J, Liu Z, Ren H, Jiang W, Wang Y, Xu Y, Guo D, Zhang X, Lu S.
    Neoplasma; 2014 Jan 24; 61(4):392-400. PubMed ID: 25027740
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.